A Shire plasma plant in Atwater Village moved one step closer to being owned by Takeda Pharmaceutical Co. Ltd. with the European Union reportedly poised to approve a $62 billion Shire deal that could impact hundreds of Los Angeles jobs. Reuters reported Nov. 9 that the Japanese drug-maker was set to win conditional EU antitrust approval for its $62 billion bid for London’s Shire. A ruling by an EU competition enforcer is expected by Nov. 20. Takeda has already won clearance from regulators in the United States, Japan, China and Brazil. The deal is expected to close by the summer of 2019.

For reprint and licensing requests for this article, CLICK HERE.